AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 226 filers reported holding AMICUS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.62 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,071,527 | -3.1% | 88,119 | +0.1% | 0.00% | +50.0% |
| Q2 2023 | $1,105,519 | +13.2% | 88,019 | -0.0% | 0.00% | 0.0% |
| Q1 2023 | $976,242 | -9.2% | 88,029 | 0.0% | 0.00% | -33.3% |
| Q4 2022 | $1,074,834 | -0.8% | 88,029 | -15.1% | 0.00% | 0.0% |
| Q3 2022 | $1,083,000 | -2.8% | 103,689 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,114,000 | +13.4% | 103,689 | 0.0% | 0.00% | +50.0% |
| Q1 2022 | $982,000 | -18.0% | 103,689 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,198,000 | +21.0% | 103,689 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $990,000 | -1.0% | 103,689 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,000,000 | -1.7% | 103,689 | +0.7% | 0.00% | 0.0% |
| Q1 2021 | $1,017,000 | -57.2% | 102,957 | 0.0% | 0.00% | -60.0% |
| Q4 2020 | $2,377,000 | +63.5% | 102,957 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $1,454,000 | -6.4% | 102,957 | 0.0% | 0.00% | -25.0% |
| Q2 2020 | $1,553,000 | +63.3% | 102,957 | 0.0% | 0.00% | +33.3% |
| Q1 2020 | $951,000 | +11.8% | 102,957 | +17.8% | 0.00% | +50.0% |
| Q4 2019 | $851,000 | +21.4% | 87,417 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $701,000 | -35.7% | 87,417 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $1,091,000 | -4.3% | 87,417 | +4.3% | 0.00% | 0.0% |
| Q1 2019 | $1,140,000 | +42.0% | 83,847 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $803,000 | -20.1% | 83,847 | +0.8% | 0.00% | -33.3% |
| Q3 2018 | $1,005,000 | -22.6% | 83,158 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,299,000 | +4.8% | 83,158 | +0.9% | 0.00% | 0.0% |
| Q1 2018 | $1,240,000 | +8.8% | 82,418 | +4.0% | 0.00% | 0.0% |
| Q4 2017 | $1,140,000 | -3.6% | 79,221 | +1.0% | 0.00% | 0.0% |
| Q3 2017 | $1,183,000 | +97.5% | 78,421 | +31.9% | 0.00% | +50.0% |
| Q2 2017 | $599,000 | +52.0% | 59,451 | +7.6% | 0.00% | +100.0% |
| Q1 2017 | $394,000 | +43.3% | 55,248 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $275,000 | -32.8% | 55,248 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $409,000 | +35.4% | 55,248 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $302,000 | -11.7% | 55,248 | +36.6% | 0.00% | 0.0% |
| Q1 2016 | $342,000 | -12.5% | 40,438 | +0.2% | 0.00% | 0.0% |
| Q4 2015 | $391,000 | -16.3% | 40,338 | +20.7% | 0.00% | -50.0% |
| Q3 2015 | $467,000 | +834.0% | 33,414 | +39.0% | 0.00% | – |
| Q1 2014 | $50,000 | -10.7% | 24,041 | 0.0% | 0.00% | – |
| Q4 2013 | $56,000 | 0.0% | 24,041 | 0.0% | 0.00% | – |
| Q3 2013 | $56,000 | 0.0% | 24,041 | 0.0% | 0.00% | – |
| Q2 2013 | $56,000 | – | 24,041 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |